Uncovering 3D bioprinting research trends: A keyword network mapping analysis
Garcia-Garcia LA., Rodriguez-Salvador M.
Laboratory Study, published in Int J Bioprint (2018) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Int J Bioprint (2018)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 33102921
- PMCID
- PMC7582012
- DOI
- 10.18063/ijb.v4i2.147
- Citations
- 6
Abstract (original English)
A scientometric analysis as part of a Competitive Technology Intelligence methodology was used to determine the main research efforts in 3D bioprinting. Papers from Scopus and Web of Science (WoS) published between 2000 and 2017 were analysed. A network map of the most frequently occurring keywords in these articles was created, and their average publication year (APY) was determined. The analysis focused on the most relevant keywords that occurred at least five times. A total of 1,759 keywords were obtained, and a co-occurrence analysis was developed for APYs with more keywords: 2011-2016. The results indicated that Polylactic Acid (PLA) is the material used most often. Applications mainly focused on bone tissue engineering and regeneration. The most frequently used technique was inkjet printing, and the main cell sources were Mesenchymal Stem Cells (MSC). From a general perspective, 'Treatment' and 'Bioink' were the most frequent keywords. The former was mainly related to cancer, regenerative medicine, and MSC and the latter, to multicellular spheroid deposition and the use of hydrogels like GelMA (gelatin methacryloyl). This analysis provides insights to stakeholders involved in 3D bioprinting research and development who need to keep abreast of scientific progress in the field.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.